Biotricity
275 Shoreline Drive, Suite 159
Redwood City
California
94065
United States
Tel: 1-800-590-4155
Website: http://biotricity.com/
137 articles about Biotricity
-
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
4/18/2024
Biotricity Inc. announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics.
-
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
4/2/2024
Biotricity Inc., a leading Technology-as-a-Service company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues.
-
Biotricity Receives Health Canada Clearance for Biotres
2/29/2024
Biotricity Inc. proudly announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market.
-
Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024
2/21/2024
Biotricity Inc. announced its financial results for the third quarter of fiscal 2024 year and ended December 31, 2023.
-
Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
2/19/2024
Biotricity Inc. announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024.
-
Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
2/14/2024
Biotricity Inc. provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency.
-
Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats
1/23/2024
Biotricity Inc., a leading medical diagnostic and consumer healthcare technology company, announced the expanding development of its future Cardiac AI Cloud platform.
-
Biotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024
11/14/2023
Biotricity Inc. announced its financial results for the second quarter of fiscal 2024 year and ended September 30, 2023.
-
Biotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14th
11/10/2023
Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023.
-
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device
10/10/2023
Biotricity, Inc. today announced its patent filing for the company's Bioheart device.
-
CORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres Device
10/4/2023
Biotricity, Inc., a Technology-as-a-Service company operating in the remote cardiac monitor sector of consumer healthcare, announced the filing of a patent application for its groundbreaking Biotres device.
-
Biotricity Announces Patient Filing for Cutting-Edge Biotres Device
10/3/2023
Biotricity, Inc. today announced the filing of a patent application for its groundbreaking Biotres device.
-
Biotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge Innovations
9/13/2023
Biotricity Inc. announced today the official launch a new digital presence that illustrates more completely the depth of Biotricity technologies and solutions.
-
Biotricity Achieves $14 Million Revenue Run Rate in August 2023
8/30/2023
Biotricity Inc. reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate.
-
Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates
8/15/2023
Biotricity Inc. today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.
-
Biotricity to Host First Quarter Fiscal Year 2024 Financial Results and Business Update Call on August 15th
8/14/2023
Biotricity Inc. announced that it will host its First Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, August 15, 2023.
-
Biotricity Shows Continued Growth and Strength in its Fundamentals on its Path to Profitability
8/11/2023
Biotricity Inc., a Technology-as-a-Service company operating in the remote cardiac monitoring sector of consumer healthcare, is pleased to report that its business continues to demonstrate strong fundamentals that are propelling the Company towards profitability.
-
Biotricity Regains Nasdaq Listing Compliance
7/21/2023
Biotricity, Inc. today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing Biotricity that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market.
-
Biotricity Reports Strong Start to Fiscal Year 2024
7/6/2023
Biotricity Inc. today reported a strong start to its Fiscal Year 2024 ending March 31, 2024 and provided a preliminary estimate of its revenue for its first quarter of fiscal year 2024.
-
Biotricity Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with Lower SG&A Driving Clear Path to Positive Cash Flow
6/30/2023
Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for its fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023.